At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SGMT Sagimet Biosciences Inc.
Pre-Mkt 10-22 05:44:41 EDT
9.99
+0.25
+2.57%
盘前10.19
+0.20+2.00%
04:06 EDT
High10.21Low9.72Vol1.58M
Open9.76D1 Closing9.74Amplitude5.03%
Mkt Cap708.38MTradable Cap675.52MTotal Shares70.91M
T/O15.71MT/O Rate2.33%Tradable Shares67.62M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Sagimet Says Partner Trial Shows Denifanstat Sustains Acne Efficacy Through 52 Weeks
Reuters  ·  10-09
Sagimet Says Partner Trial Shows Denifanstat Sustains Acne Efficacy Through 52 Weeks
Sagimet Biosciences Price Target Maintained with a $29.00/Share by HC Wainwright & Co.
Dow Jones  ·  10-05
Sagimet Biosciences Price Target Maintained with a $29.00/Share by HC Wainwright & Co.
Sagimet Biosciences price target raised to $26 from $25 at Guggenheim
TIPRANKS  ·  10-02
Sagimet Biosciences price target raised to $26 from $25 at Guggenheim
Sagimet Biosciences Closes Offering of Shares, Warrants
MT Newswires Live  ·  10-02
Sagimet Biosciences Closes Offering of Shares, Warrants
Sagimet Biosciences Announces Closing of Underwritten Offering of Series a Common Stock and Pre-Funded Warrants
THOMSON REUTERS  ·  10-02
Sagimet Biosciences Announces Closing of Underwritten Offering of Series a Common Stock and Pre-Funded Warrants
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
GlobeNewswire  ·  10-02
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
Sagimet Biosciences Phase 3 Trial of Denifanstat as Acne Treatment Has High Success Probability, Wedbush Says
MT Newswires Live  ·  10-01
Sagimet Biosciences Phase 3 Trial of Denifanstat as Acne Treatment Has High Success Probability, Wedbush Says
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)
TIPRANKS  ·  10-01
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)
Oppenheimer Adjusts Price Target on Sagimet Biosciences to $38 From $33, Maintains Outperform Rating
MT Newswires Live  ·  10-01
Oppenheimer Adjusts Price Target on Sagimet Biosciences to $38 From $33, Maintains Outperform Rating
Sagimet Biosciences Inc. : Oppenheimer Raises Target Price to $38 from $33
THOMSON REUTERS  ·  10-01
Sagimet Biosciences Inc. : Oppenheimer Raises Target Price to $38 from $33
Sagimet Biosciences Announces Major Equity Financing Agreement
TIPRANKS  ·  10-01
Sagimet Biosciences Announces Major Equity Financing Agreement
Sagimet Biosciences’ China data strengthens denifanstat case, says Clear Street
TIPRANKS  ·  10-01
Sagimet Biosciences’ China data strengthens denifanstat case, says Clear Street
Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell
MT Newswires Live  ·  09-30
Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell
Sagimet Biosciences prices 8.75M shares at $10.00 in underwritten offering
TIPRANKS  ·  09-30
Sagimet Biosciences prices 8.75M shares at $10.00 in underwritten offering
Sagimet Biosciences - Prices 8.8 Mln Series a Common Shares at $10 Per Share
THOMSON REUTERS  ·  09-30
Sagimet Biosciences - Prices 8.8 Mln Series a Common Shares at $10 Per Share
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series a Common Stock and Pre-Funded Warrants
THOMSON REUTERS  ·  09-30
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series a Common Stock and Pre-Funded Warrants
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
GlobeNewswire  ·  09-30
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
Sagimet Biosciences - Suspends and Terminates ATM Prospectus Supplement for Series a Common Stock Effective Sept 30
Reuters  ·  09-30
Sagimet Biosciences - Suspends and Terminates ATM Prospectus Supplement for Series a Common Stock Effective Sept 30
Sagimet Biosciences - Suspends and Terminates Atm Prospectus Supplement for Series a Common Stock Effective Sept 30 - SEC Filing
THOMSON REUTERS  ·  09-30
Sagimet Biosciences - Suspends and Terminates Atm Prospectus Supplement for Series a Common Stock Effective Sept 30 - SEC Filing
Sagimet Biosciences reports results from Phase 3 ASC40-304 OLE clinical trial
TIPRANKS  ·  09-30
Sagimet Biosciences reports results from Phase 3 ASC40-304 OLE clinical trial

Introduction

Company Name.
Sagimet Biosciences Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Issue price:
--